Showing results (51-60 of 229) with videos related to

Sort By:
Pageof 23
The Journal of Rheumatology|February 12, 2009
Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosusMandana Nikpour, Dafna D Gladman, Dominique Ibañez, et al.
Arthritis and Rheumatism|April 3, 2008
The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritisSophia M Naz, Tracey M Farragher, Diane K Bunn, et al.
Scientific Reports|March 2, 2016
Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosusJohn A Reynolds, Sahena Haque, Kate Williamson, et al.
Lupus Science & Medicine|July 27, 2024
Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD)Jessica Ellis, Neil McHugh, John D Pauling, et al.
Autoimmunity Reviews|May 25, 2025
Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumabBeatriz Frade-Sosa, Juan C Sarmiento-Monroy, Ian N Bruce, et al.
BMJ Open Respiratory Research|January 9, 2021
Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology servicesShaney L Barratt, Havra H Adamali, Caroline Cotton, et al.
Pharmacoeconomics|January 31, 2012
Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisalHuiqin Yang, Dawn Craig, David Epstein, et al.
Annals of the Rheumatic Diseases|January 16, 2007
HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritisPauline Y P C Ho, Anne Barton, Jane Worthington, et al.
Lupus Science & Medicine|May 31, 2022
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trialStephen McDonald, Sean Yiu, Li Su, et al.
Lupus Science & Medicine|February 11, 2021
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programmeToni Maslen, Ian N Bruce, David D'Cruz, et al.
Pageof 23